Literature DB >> 19407314

Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.

Matteo Giovanni Della Porta, Luca Malcovati.   

Abstract

Myelodysplastic syndromes occur mainly in older persons, and these patients are likely to have comorbidities that significantly worsen their survival. In this perspective article, Drs. Della Porta and Malcovati examine the relevance of comorbidities for clinical decision making in patients with myelodysplasti syndromes.

Entities:  

Mesh：

Year:  2009        PMID： 19407314      PMCID： PMC2675669          DOI： 10.3324/haematol.2009.005702

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  19 in total

1.  Myelodysplastic syndromes--coping with ineffective hematopoiesis.

Authors:  Mario Cazzola; Luca Malcovati
Journal:  N Engl J Med       Date:  2005-02-10       Impact factor: 91.245

2.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

Authors:  L F Hutchins; J M Unger; J J Crowley; C A Coltman; K S Albain
Journal:  N Engl J Med       Date:  1999-12-30       Impact factor: 91.245

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.

Authors:  Lazzaro Repetto; Lucia Fratino; Riccardo A Audisio; Antonella Venturino; Walter Gianni; Marina Vercelli; Stefano Parodi; Denise Dal Lago; Flora Gioia; Silvio Monfardini; Matti S Aapro; Diego Serraino; Vittorina Zagonel
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

5.  Comparison of comorbidity indices for patients with head and neck cancer.

Authors:  Jay F Piccirillo; Edward L Spitznagel; Nisha Vermani; Irene Costas; Mark Schnitzler
Journal:  Med Care       Date:  2004-05       Impact factor: 2.983

6.  No increase in age-specific incidence of myelodysplastic syndromes.

Authors:  Ulrich Germing; Corinna Strupp; Andrea Kündgen; David Bowen; Carlo Aul; Rainer Haas; Norbert Gattermann
Journal:  Haematologica       Date:  2004-08       Impact factor: 9.941

7.  Undertreatment strongly decreases prognosis of breast cancer in elderly women.

Authors:  Christine Bouchardy; Elisabetta Rapiti; Gérald Fioretta; Paul Laissue; Isabelle Neyroud-Caspar; Peter Schäfer; John Kurtz; André-Pascal Sappino; Georges Vlastos
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

8.  Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

Authors:  Emilio Paolo Alessandrino; Sergio Amadori; Giovanni Barosi; Mario Cazzola; Alberto Grossi; Lucio N Liberato; Franco Locatelli; Monia Marchetti; Enrica Morra; Paolo Rebulla; Giuseppe Visani; Sante Tura
Journal:  Haematologica       Date:  2002-12       Impact factor: 9.941

9.  The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.

Authors:  Esther Zipperer; Daniela Pelz; Kathrin Nachtkamp; Andrea Kuendgen; Corinna Strupp; Norbert Gattermann; Rainer Haas; Ulrich Germing
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

10.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272
View more
  11 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool.

Authors:  Matteo G Della Porta; Ilaria Ambaglio; Marta Ubezio; Erica Travaglino; Cristiana Pascutto; Luca Malcovati
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

3.  Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.

Authors:  Naval Daver; Kiran Naqvi; Elias Jabbour; Tapan Kadia; Courtney DiNardo; Marylou Cardenas-Turanzas; Sherry Pierce; Khanh Thi-Thuy Nguyen; Carlos Bueso-Ramos; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2014-02-21       Impact factor: 10.047

4.  Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

5.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

6.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Authors:  Matteo G Della Porta; Luca Malcovati; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Esther Zipperer; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

7.  Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.

Authors:  Kiran Naqvi; Guillermo Garcia-Manero; Sagar Sardesai; Jeong Oh; Carlos E Vigil; Sherry Pierce; Xiudong Lei; Jianqin Shan; Hagop M Kantarjian; Maria E Suarez-Almazor
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

8.  The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.

Authors:  Roberto Castelli; Riccardo Schiavon; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-02-08       Impact factor: 3.064

9.  A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

Authors:  Flavia Mayer; Laura Faglioni; Nera Agabiti; Susanna Fenu; Francesco Buccisano; Roberto Latagliata; Roberto Ricci; Maria Antonietta Aloe Spiriti; Caterina Tatarelli; Massimo Breccia; Giuseppe Cimino; Luana Fianchi; Marianna Criscuolo; Svitlana Gumenyuk; Stefano Mancini; Luca Maurillo; Carolina Nobile; Pasquale Niscola; Anna Lina Piccioni; Agostino Tafuri; Giulio Trapè; Alessandro Andriani; Paolo De Fabritiis; Maria Teresa Voso; Marina Davoli; Gina Zini
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-07-01       Impact factor: 2.576

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.